A national dialogue is needed around the value of new medicines and cures and the role they play in improving patient health and helping to manage long-term spending in the U.S. health care system. Unfortunately, the debate around hepatitis C has, for the most part, been twisted to the point that modern-day cures are seen as a nuisance rather than a monumental step forward in the battle against disease. (This post was updated on August 5, 2014.)
Most Recent Posts
For many patients, hope for a brighter future is directly tied to the potential of medicines in the pipeline to treat their disease or condition.
Today, more than 52 million Americans are affected by arthritis and related musculoskeletal diseases, consisting of more than 100 different conditions, according to the U.S. Centers for Disease Control and Prevention (CDC). The CDC projects prevalence of musculoskeletal diseases could increase to 67 million by 2030 if current trends continue.
Medicare Part D continues to be a success for beneficiaries.
This week was packed with lively and informative discussions surrounding the incredibly important issue of treatment costs and the need to incorporate value into the cost narrative.
Following up on our May post, the next chapter in the rebuilding of the U.S. – India relationship has begun, as U.S. Secretary of State John Kerry and Secretary of Commerce Penny Pritzker are in India to meet with their counterparts in the new Indian government. Secretary Kerry will partake in the fifth U.S.-India Strategic Dialogue and also meet with Prime Minister Modi, the first meetings to occur between high-ranking officials from the U.S.
For the millions of patients battling hepatitis C, World Hepatitis Day will hopefully be a day that is only read about in history books.
Now, more than ever before, there is great hope on the horizon as new and forthcoming medicines can provide nearly all patients fighting this disease with a cure.
Biopharmaceutical research and development (R&D) continues to thrive. This week, we examined some of the ways that medicines in development have opened new doors for patients and what we can do to maintain a bright and promising future.
The current debate regarding the cost of new and forthcoming hepatitis C treatments has brought to light a long-standing discussion about the cost and value of innovative new medicines.
As part of the 21st Century Cures initiative, the House Energy and Commerce Subcommittee on Health discussed barriers to evidence development and communication for medicines and devices.
Mental health conditions affect 1 in 4 Americans and take a heavy economic toll on the United States. Efforts to find effective treatments for conditions such as anxiety, depression, schizophrenia and substance abuse disorders continue despite difficult hurdles and setbacks.
A recent article in the New York Times once again missed the mark when it comes to reporting on the great promise in the biopharmaceutical pipeline.
Pharmacology is often described as a bridge science because it incorporates knowledge and skills from a number of basic science disciplines including physiology, biochemistry and cell and molecular biology. Pharmacologists are able to 'translate' such knowledge into the rational development of therapeutics. As a result of their multidisciplinary training, pharmacologists are able to offer a unique perspective in solving drug-, hormone- and chemical-related problems.
A ProPublica story from yesterday, “Error: You Have No Payments from Pharma,” details the difficulties physicians face while trying to register with the CMS Open Payments system. And while it only focused on a narrow group of physicians, ProPublica’s findings reflect a much larger problem. It isn’t just a select group of physicians who are having difficulties registering with the CMS Open Payment’s system; many physicians are facing similar issues.